Lead Sponsor

Tanabe Pharma Corporation

Age

20 - 75 years

Sex

ALL

Healthy Volunteers

No

•Patients who are 20 - 75 years old
•Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug
•Patients whose HbA1c is between 7.0% and 10.0%
•Patients who took Sulfonylurea for diabetes over 12 weeks before administration of investigational drug
•Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug

•Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc)
•Patients with Class III/IV heart failure symptoms according to NYHA functional classification
•Patients who are gastrointestinal disorder (diarrhea, vomiting)
•Patients with serious diabetic complications
•Patients who are the excessive alcohol addicts
•Patients with severe hepatic disorder or severe renal disorder
•Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception